Hemostemix increases private placement to $3 million

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) increased the size of its previously closed private placement from $2,969,600 to $3,000,000, according to a company statement.

The Calgary-based stem cell therapy company issued an additional 3,000,000 units at $0.10 per unit following receipt of additional subscriptions not included in the original offering that closed on July 23, 2025.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.15 for 24 months from the closing date, subject to an acceleration clause if the stock price exceeds a weighted average of $0.185 per share for 10 consecutive trading days after four months.

The company paid $100,032 in finder's fees and issued 1,000,320 finder's options in connection with the increased offering. Each finder's option permits the purchase of one common share at $0.15, exercisable for 24 months.

Proceeds will be used to repay CD#1 in full at a 50% discount to face value totaling $1,250,000 and for general working capital to support operational expenses, including marketing and sales of VesCell.

The transaction constitutes a related party transaction as directors Peter Lacey and Loran Swanberg participated in the offering. Following the transaction, Lacey's ownership increased from 6.14% to 13.40% on a non-diluted basis after subscribing to 15,000,000 units.

Hemostemix develops autologous stem cell therapy and has completed seven clinical studies involving 318 subjects. The company's ACP-01 treatment has been tested for peripheral arterial disease and various cardiac conditions.

You May Also Be Interested In

• Enerpac Tool Group to buy SFE Group for $472 million
• Morgan Stanley Upgrades Ivanhoe Mines Ltd. (IVN:CN) (IVPAF) to Overweight
• Baird Starts Midera Food Processing (MFPVV) at Neutral